TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
ARVN

Arvinas Inc

Healthcare · Biotechnology

8.30$ +1.8% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns Arvinas Inc (ARVN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 86.9% of the shares are freely tradable; institutional investors hold 83.3%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 83.3%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 7.8%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 86.9%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 8.4%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 65Mio.

Largest Shareholders

Institutions

Institutions ARVN
Name Stake (%) Shares Change (%) Date
BlackRock Inc 10.40 6,797,584 -7.2 03/31/2026
Vanguard Portfolio Management, LLC 5.95 3,889,628 +0.0 03/31/2026
D. E. Shaw & Co LP 5.35 3,495,153 -3.9 06/30/2026
Pfizer Inc 5.29 3,457,815 +0.0 03/31/2026
Vanguard Capital Management, LLC 4.11 2,689,362 +0.0 03/31/2026
Two Sigma Investments LLC 3.94 2,573,447 +40.5 06/30/2026
Armistice Capital, LLC 3.03 1,978,000 +9.9 03/31/2026
State Street Corp 2.80 1,828,472 -0.8 03/31/2026

Funds

Funds ARVN
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 2.94 1,920,682 +0.0 07/31/2026
Vanguard Strategic Equity Inv 2.62 1,709,917 +5.6 06/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?